Simple Blood Test Detects Alzheimer's 15-20 Years Before Symptoms

Hi Phoenix Friends,
The FDA approved a few months ago (May 2025) the p-tau217 test.
If you ever wanted to learn more about the test, and other innovative biomarkers, I cover the AAIC 2025 session about biomarkers advancements.

In this video, I analyzed 9 breakthrough presentations from the world's leading biomarker researchers:

- P-tau217 blood test: 97% accurate (two-cutoff method)
- 6-min MRI (QGRE): Detects 5-10% neuron loss vs 20-30% for standard MRI
- Mobile Toolbox: NIH app detects changes 7 years early via "loss of practice effect"
- AI Prediction: 85% accurate timeline prediction within 2-3 years
- MTBR Tracking: Measures tau's most dangerous form at 10 picograms/mL
-And more!

Full conference analysis:

Session Presenter(s):

• Daeun Shin (Samsung Medical Center, Seoul, Korea, Republic of (South)) - Biomarker-integrated Prognostic Stagings for Alzheimer's Disease

• Satya V.V.N. Kothapalli (Washington University School of Medicine in St. Louis, MO, USA) - Pre-atrophic Neurodegeneration: A Novel MRI-Based Biomarker for Early Neuronal Injury Coincident with Early Amyloid Accumulation

• Noëlle Warmenhoven (Lund University, Sweden) - Comparison of plasma biomarkers measured on a fully automated instrument versus CSF biomarkers for detecting Alzheimer’s disease pathology

• Xiaqing Jiang (University of California, San Francisco, CA, USA) - AT(N) Biomarkers Across Modalities in the Pathways Between Multimorbidity and Cognition

• Katie L. Vandeloo (Hurvitz Brain Sciences Program, Sunnybrook Research Institute, ON, Canada) - Sex-Specific Associations Between Systemic Inflammation and Brain Health in Aging: Evidence from a Multi-Ethnic Canadian Cohort

• María Fernanda Zambrano-Astorga (CICESE, BJ, Mexico) - Identification of an Alzheimer’s Disease Biomarker Signature Using Reproducible Proteomics Data Mining

• Christopher S. Parker (UCL Hawkes Institute and Department of Computer Science, University College London, United Kingdom; Dementia Research Centre, Queen Square Institute of Neurology, Greater London, United Kingdom) - Longitudinal trajectories of advanced cortical diffusion-weighted imaging measures of tissue microstructure in pre-symptomatic autosomal dominant Alzheimer’s disease

• Roos J. Jutten (Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Netherlands) - The remote Mobile Toolbox for capturing cognitive change in preclinical Alzheimer’s disease

• Fernando Gonzalez-Ortiz (University of Gothenburg, Department of Psychiatry And Neurochemistry, Institute of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg, Sweden) - Novel MTBR-specific immunoassays MTBR-1 and MTBR-pTau262 for assessment of tau pathology in Alzheimer's disease